58728 Federal Register / Vol. 70, No. 194 / Friday, October 7, 2005 / Notices 

MSC 7844, Bethesda, MD 20892, (301) 435–

2212, josephru@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Bioengineering Research Partnerships—

Biomedical Sensing. 

Date: October 27, 2005. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Pushpa Tandon, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5104, 

MSC 7854, Bethesda, MD 20892, (301) 435–

2397, tandonp@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, RIBT 

Member Conflicts. 

Date: October 27, 2005. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: George M. Barnas, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health 6701 Rockledge Drive, Room 2180, 

MSC 7818, Bethesda, MD 20892, (301) 435–

0696, barnasg@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Nuclear 

Membrane Proteins. 

Date: October 27, 2005. 

Time: 2 PM to 3 PM. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health; 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Jonathan Arias, PHD, 

Scientific Review Administrator, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 5170 MSC 7840, Bethesda, MD 20892, 

301–435–2406, ariasj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Approaches 

in Cancer Therapeutics. 

Date: October 27, 2005. 

Time: 3 PM to 5 PM. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Joanna M. Watson, PHD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6046–G, 

MSC 7804, Bethesda, MD 20892, 301–435–

1048, watsonjo@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 30, 2005. 

Anthony M. Coelho, Jr. 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–20254 Filed 10–6–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: North-2’-DeoxyMethanocarbathmydines as Antiviral 

Agents Against Poxvirus 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services (HHS), is 

contemplating the grant of an exclusive 

license to practice the following 

invention as embodied in the following 

patent applications: HHS Ref. No. E–

047–2005; U.S. Provisional Patent 

Application Number 60/684,811, filed 

on May 25, 2005 to N&N Scientific, 

having a place of business in Maryland 

but incorporated in Illinois. The patent 

rights in these inventions have been 

assigned to the United States of 

America. 

DATES: Only written comments and/or 

application for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

December 6, 2005 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Robert M. Joynes, Office of 

Technology Transfer, National Institutes 

of Health, 6011 Executive Boulevard, 

Suite 325, Rockville, MD 20852–3804; 

E-mail: joynesr@od.nih.gov; Telephone: 

(301) 594–6565; Facsimile: (301) 402–

0220. 

SUPPLEMENTARY INFORMATION: The 

prospective exclusive license will be 

royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. The 

field of use may be limited to the 

treatment of poxviruses. 

The subject invention relates to a 

method for the prevention or treatment 

of poxvirus infection by administering 

an effective amount of an antiviral agent 

comprising a carbocyclic 2’- 

deoxynucleoside analog (as described in 

U.S. Patent Nos. 5,629,454 and 

5,869,666) to an individual in need 

thereof. North-methanocarbathymidine 

(N–MCT), a thymidine analog with a 

pseudosugar moiety locked in the 

northern conformation, which was 

previously shown to exert strong 

activity against herpes simplex virus 

types 1 and 2, has been identified as 

exhibiting potent activity against 

poxviruses. N–MCT effectively blocks 

poxvirus synthesis through its 

phosphorylated metabolite, which is 

more efficiently produced in poxvirusinfected cells. This compound is 

approximately seven times more potent 

than cidofovir against vaccinia and 

cowpox in cell culture. The higher 

potency and target specificity of N–MCT 

against poxvirus, as well as its high 

margin of safety, makes it a highly 

desirable agent against the poxviridae 

family. In addition, the mechanism of 

N–MCT may be different from that of 

cidofovir, making it even more desirable 

due to the scarcity of the potential 

available efficacious anti-pox agents 

currently under development. 

The licensed territory will be 

exclusive worldwide. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: September 27, 2005. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 05–20242 Filed 10–6–05; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Office of the Secretary 

Senior Executive Service Performance 

Review Board 

AGENCY: Office of the Secretary, DHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

appointment of the members of the 

Senior Executive Service Performance 

Federal Register / Vol. 70, No. 194 / Friday, October 7, 2005 / Notices 58729 

Review Boards for the Department of 

Homeland Security. The purpose of the 

Performance Review Board is to review 

and make recommendations concerning 

proposed performance appraisals, 

ratings, bonuses, pay adjustments, and 

other appropriate personnel actions for 

incumbents of Senior Executive Service 

positions of the Department. 

EFFECTIVE DATES: This Notice is effective 

October 7, 2005. 

FOR FURTHER INFORMATION CONTACT: 

Carmen Arrowood, Office of the Chief 

Human Capital Office, telephone (202) 

357–8348. 

SUPPLEMENTARY INFORMATION: Each 

Federal agency is required to establish 

one or more performance review boards 

(PRB) to make recommendations, as 

necessary, in regard to the performance 

of senior executives within the agency. 

5 U.S.C. 4314(c). This notice announces 

the appointment of the members of the 

PRB for the Department of Homeland 

Security (DHS). The purpose of the PRB 

is to review and make recommendations 

concerning proposed performance 

appraisals, ratings, bonuses, pay 

adjustments, and other appropriate 

personnel actions for incumbents of SES 

positions within DHS. 

The Board shall consist of at least 

three members. In the case of an 

appraisal of a career appointee, more 

than half of the members shall consist 

of career appointees. Composition of the 

specific PRBs will be determined on an 

ad hoc basis from among the individuals 

listed below: 

Adamoli, Joseph B. 

Adams, Audrey L. 

Aguilar, David V. 

Ahern, Jayson P. 

Alexander, Jane A. 

Arcos, Cresencio 

Balaban, Richard L. 

Bathurst, Donald G. 

Beardsworth, Richard 

Bergman, Cynthia L. 

Besanceney, Brian R. 

Blair, James D. 

Bone, Craig, E. RADML 

Boudreaux, Chad 

Boyd, David G. 

Brice-O’Hara, Sally RADM 

Broderick, Matthew E. 

Buikema, Edward G. 

Cannatti, Ashley 

Charbo, Lawrence Scott 

Cira, Anthony Thomas 

Cuddihy, Joseph D. 

Currier, John P. RADML 

DiGregorio, Elizabeth L. 

Dinanno, Thomas G. 

Dolan, Kay Frances 

Dooher, John C. 

Duke, Elaine C. 

Dunham, Carol A. 

Dunlap, James L. 

Fagerholm, Eric N. 

Filler, Joshua D. 

Forman, Marcy M. 

Fonash, Peter M. 

Hale, Janet 

Hall, Michael J. 

Hasting, Charles R. 

Hastings, Scott O. 

Hill, Kenneth 

Holcomb, Lee B. 

Irving, Paul D. 

James, Ronald J. 

Jones, Rendell L. 

Kelleher, John J. 

Kent, Donald H. 

Khatri, Prakash I. 

Kubricky, John J. 

Kunkel, David W. RADM 

Ladd, Paul E. 

Lang, Gary J. 

Langlois, Joseph E. 

Lederer, Calvin M. 

Lockwood, Thomas 

Lumsden, Sheila 

Lynch, Dennis F. 

MacDonald, John R. 

Mandelker, Sigal P. 

Maner, Andrew B. 

Martinez-Fonts, Alfonso 

Matticks, John 

Maursstad, David I. 

Mayer, Matt A. 

McCampbell, Christy 

McCarthy, Maureen I. 

McDonald, Sallie 

McKennis, Amy D. 

McNamara, John C. 

McQueary, Charles E. 

Mitchell, Andrew 

Mocny, Robert A. 

Nagel, Brian K. 

Nimmich, Joseph L. RDML 

O’Neill, James P. 

O’Reilly, Terrance M. 

Ostergaard, Daniel J. 

Oxford, Vayl S. 

Paar, Thomas C. 

Parent, Wayne 

Prewitt, Keith L. 

Prillaman, K. Gregg 

Quinn, Thomas 

Reyes, Juan 

Richmond, Susan 

Riggs, Barbara S. 

Robles, Alfonso 

Rogers, George D. 

Rossides, Gale D. 

Rothwell, Gregory D. 

Runge, Jeffrey W. 

Santana, Catherine Y. 

Schied, Eugene H. 

Schmitz, Michael T. 

Shingler, Wendell C. 

Sirois, R. Dennis RADM 

Smith, Robert M. 

Sposato, Janis A. 

Stalhschmidt, Patricia K. 

Stallworth, Charles E. 

Stenger, Michael C. 

Stephan, Robert B. 

Stephens, Michael P. 

Sullivan, Daniel 

Sullivan, Mark J. 

Sutherland, Daniel W. 

Tambone, Victor J. 

Teufel, Hugo 

Thomson, E. Keith 

Torres, John 

Trissell, David A. 

Turner, Pamela J. 

Turner, Todd H. 

Vanacore, Michael J. 

Venuto, Kenneth T. RADM 

Vint, Norbert E. 

Walker, Carmen H. 

Weber, Robert W. 

West, Robert C. 

Whitehead, Joel R. RDML 

Whitford, Richard A. 

Wiggins, Michael 

Williams, Dwight 

Williams, James A. 

Williams, Richard N. 

Wood, John F. 

Woodson, Mary Ann 

This notice does not constitute a 

significant regulatory action under 

section 3(f) of Executive Order 12866. 

Therefore, DHS has not submitted this 

notice to the Office of Management and 

Budget. Further, because this notice is a 

matter of agency organization, 

procedure and practice, DHS is not 

required to follow the rulemaking 

requirements under the Administrative 

Procedure Act (5 U.S.C. 553). 

Dated: September 30, 2005. 

Rodney Markham, 

Director, Executive Resources, Office of the 

Chief Human Capital Office. 

[FR Doc. 05–20167 Filed 10–6–05; 8:45 am] 

BILLING CODE 4410–10–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

DEPARTMENT OF TRANSPORTATION 

Maritime Administration 

[USCG–2005–22611] 

Neptune LNG, L.L.C., Liquefied Natural 

Gas Deepwater Port License 

Application 

AGENCY: Coast Guard, DHS; Maritime 

Administration, DOT. 

ACTION: Notice of application. 

SUMMARY: The Coast Guard and the 

Maritime Administration (MARAD) 

announce that they have received an 

application for the licensing of a